← BioMarin Pharmaceutical Inc. (BMRN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioMarin Pharmaceutical Inc. (BMRN)
Pharmaceutical Preparations · market cap $12.0B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-26 (est.)
Earnings
Pipeline
20
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
BioMarin Pharmaceutical (BMRN) is a rare-disease biotech with two approved products — Voxzogo (achondroplasia) and Roctavian (hemophilia A) — and a deep pipeline spanning PKU, MPS, DMD, and bone dysplasias. The company generated $3.22B in 2025 revenue and carries a net cash position of ~$792M against an $11.6B market cap (~$60/share). Lead pipeline asset BMN 110-Weekly (MPS IVA) is in Phase 3, with vosoritide extensions and BMN 351 (DMD) as the next meaningful readouts.
The catalyst path
- 2026-10-26 (est.)Earningsimp 5/10
- 2027-02-28NDA Filingimp 7/10
- 2027-02-28PDUFAimp 8/10
- 2027-03-15 (est.)Phase 2 · Vosoritide Injectionimp 7/10
- 2027-04-14 (est.)Phase 2 · BMN 351imp 7/10
- 2027-07-09 (est.)PDUFA · Voxzogoimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Voxzogo | Approved | Achondroplasia |
| Roctavian | Approved | Hemophilia A |
| BMN 331 | Phase 1/2 | Phenylketonuria |
| BMN 110 - Weekly | Phase 3 | Mucopolysaccharidosis IV A |
| Human Growth Hormone | Phase 2 | Idiopathic Short Stature |
| sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | Phase 3 | Phenylketonurias |
| Valoctocogene roxaparvovec | Phase 3 | Hemophilia A With Inhibitor |
| BMN 165 | Phase 3 | Phenylketonuria |
| BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) | Phase 2 | Jansky-Bielschowsky Disease |
| Vosoritide Injection | Phase 2 | Short Stature Homeobox- Containing Gene SHOX Deficiency |
| Kuvan® | Phase 3 | Phenylketonuria |
| rAvPAL-PEG | Phase 2 | Phenylketonuria |
| BMN 110 Weekly | Phase 3 | MPS IV A |
| Phenoptin | Phase 2 | Tetrahydrobiopterin Deficiencies |
| BMN 701 | Phase 2 | Pompe Disease |
| BMN 111 | Phase 3 | Achondroplasia |
| BMN 351 | Phase 2 | Duchenne Muscular Dystrophy |
| 6R-BH4 (sapropterin dihydrochloride) | Phase 2 | Hypertension |
| BMN 307 | Phase 2 | Phenylketonuria (PKU) |
| N-acetylgalactosamine 4-sulfatase | Phase 3 | Mucopolysaccharidosis VI |
Price & technical context
3-month
+3.8%
6-month
+6.2%
12-month
+10.8%
52-wk range
$49.67–$70.24
vs 50-day MA
-6.3%
vs 200-day MA
+2.4%
Realized vol
34.8%
Max drawdown
-41.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BMRN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.